Surgery is the cornerstone of oncology treatment, and molecularly-targeted fluorescent imaging agents have the potential to guide surgical resection by highlighting the biological margins of the disease. However, development and testing of such molecular imaging agents has been lacking. Thayer School of Engineering and Geisel School of Medicine at Dartmouth together with LI-COR Biosciences and Affibody AB announce a new Academic/Industry Partnership to establish an efficient pipeline for development and translation of molecularly-targeted agents. The five-year project is funded by the National Cancer Institute.
This groundbreaking study will use a cost-effective, risk-diluted approach for rapid development and testing of molecularly-targeted imaging agents in phase 0 microdosing studies. The microdosing studies are designed to evaluate imaging of specific targets.